Amedisys (NASDAQ:AMED) reported Q1 EPS of $1.23, $0.11 better than the analyst estimate of $1.12. Revenue for the quarter came in at $545.3 million versus the consensus estimate of $558.84 million.
GUIDANCE:
Amedisys sees FY2022 EPS of $5.23-$5.45, versus the consensus of $5.33. Amedisys sees FY2022 revenue of $2.33-2.365 billion, versus the consensus of $2.36 billion.
For earnings history and earnings-related data on Amedisys (AMED) click here.